Pancreatic Cancer Therapeutic Vaccines: Evidence Review of 7 Projects (2026)
Pancreatic cancer (PDAC) is one of the hardest cancers to treat. Five-year survival sits around 9–12% globally. But a new wave of therapeutic vaccines — designed to train the patient’s own immune system to recognize and attack tumor cells — is generating real hope. And real hype.
This report reviews 7 pancreatic cancer vaccine projects with verified clinical data, trial registrations, and peer-reviewed publications. We grade each one by evidence strength and risk level, so you can separate the signal from the noise.
Important: This is not medical advice. Always consult your treating physician before making treatment decisions. The data below is based on publicly available information as of April 2026.
Evidence Grading Framework
We use two scales in parallel:
Data Level (for pancreatic cancer treatment benefit):
- A: Randomized controlled trial + clear clinical endpoints (RFS/OS) + adequate sample + full safety profile
- B: Peer-reviewed pancreatic cancer data with clinical endpoints, but early/non-randomized/small sample
- C: Verifiable clinical trial registration / IND, but public results mainly immunological endpoints or abstract-level signals
- D: No verifiable registration or only marketing claims
Risk Level:
- Low: Published data shows mainly mild-moderate adverse events
- Medium: Regimen expected to bring ≥Grade 3 toxicity or requires systematic monitoring
- High: Known mechanism with historical fatal/severe adverse events, or combination significantly elevates risk
The 7 Projects: Evidence Summary
1. Neo-P DC (Japan) — Neoantigen Long/Short Peptide Pulsed Dendritic Cells
Evidence Level: B | Risk: Low
The strongest evidence in this review. A peer-reviewed retrospective study of 16 post-operative PDAC patients showed:
- 81.3% (13/16) developed neoantigen-specific T cells
- In 9 patients vaccinated after recurrence: those with immune response had longer OS
- In 7 patients vaccinated as adjuvant (post-surgery): at median 61-month follow-up, only 1 recurrence, zero deaths. The single recurrence was treated with radiofrequency ablation and remained disease-free for 50+ months
- Zero adverse reactions reported, all patients completed 6 treatment cycles
Limitations: Non-randomized, extremely small sample. Adjuvant group was mostly Stage I–II with concurrent systemic therapy — selection bias and treatment confounders cannot be excluded. “Immune response correlates with survival” ≠ “proven causal efficacy.”
2. WT1 DC (WT1-Targeted Dendritic Cell Vaccine)
Evidence Level: B | Risk: Medium
Unresectable advanced PDAC (Phase I): 10 patients received WT1-DC combined with chemotherapy. Reported disease control, partial responses, and a notably high conversion surgery rate (5/10). Median PFS: 2.23 years, OS: 3.52 years.
Resectable post-surgery adjuvant (Phase I): 8 patients combined with gemcitabine. Reported WT1-specific CTL responses with only Grade 1 fever and injection site reactions.
Limitations: Small sample, single-arm Phase I. Tightly coupled with chemotherapy — the independent contribution of WT1-DC cannot be estimated. WT1 as a “shared antigen” has shown variable efficacy across studies.
3. PCNAT-01 / PCNAT-1 (Anda Biotech — Personalized Neoantigen Peptide Vaccine)
Evidence Level: C | Risk: Medium
Verifiable trial design: single-center, open-label Phase I, targeting post-chemotherapy PDAC patients. Vaccine composed of multiple personalized peptides with poly-ICLC adjuvant.
Clinical outcome signal (abstract/review level only): A review in Journal of Clinical Investigation cited a preliminary abstract reporting 3/4/5-year RFS of 60%/52.5%/43.8%, noting that treatment benefit needs further confirmation.
Red flag: Multiple investment/PR articles claim FDA Orphan Drug Designation and “significant survival improvement,” but the actual auditable long-term RFS numbers come from preliminary abstracts — not fully published, peer-reviewed data with complete patient demographics, staging, margin status, and follow-up protocols.
4. P01 (iNeo-Vac-P01 — Personalized Neoantigen Peptide Vaccine)
Evidence Level: B | Risk: Low-Medium
Advanced refractory PDAC: Published in Frontiers in Immunology — 7 patients, average OS 24.1 months, PFS 3.1 months, with documented TCR clonal expansion. Authors emphasized exploratory nature and small sample.
Post-surgery anti-recurrence (NCT04810910): Phase I with RFS/OS as endpoints. Conference abstract disclosed: 9 PDAC patients enrolled 2021–2025, median follow-up 35.6 months, mRFS not reached, 3-year RFS rate 83.3%, all alive during follow-up.
Limitations: Post-surgery data is conference abstract level with only 9 patients and mixed staging. The impressive RFS/OS numbers are better treated as “signal” rather than confirmed conclusions.
5. LK101 (Personalized Vaccine/Cell Vaccine)
Evidence Level: C | Risk: Medium
Public registrations (NCT06054932, NCT05886439) focus on late-stage solid tumors and lung cancer. Primary endpoints are safety, DLT, and immune response. No published pancreatic cancer-specific efficacy data yet.
For PDAC patients, this remains a “platform with potential, evidence pending.”
6. XH001 (Xinhe Bio — Personalized mRNA Neoantigen Vaccine)
Evidence Level: C | Risk: Medium
Verifiable as a multi-center, open-label Phase I targeting “high-recurrence-risk post-surgical solid tumors” including PDAC. Core endpoints: safety, tolerability, recommended dose.
No published RFS/OS/recurrence rate readouts yet. Judgment for “post-surgery adjuvant benefit in PDAC” can currently only be made at the mechanism and trial design level.
7. RGL-270 (Ruipuxiang — Personalized mRNA Neoantigen Vaccine)
Evidence Level: C | Risk: Medium-High (if combined with PD-L1)
Multi-center, open Phase I. Entry focused on “post-surgical, no recurrence/metastasis” solid tumor patients. Includes a cohort combined with immune checkpoint inhibitors — which means irAE risk management must be front-loaded.
As of early 2025, minimal public enrollment data. In the absence of a complete safety profile (especially ≥Grade 3 AE/irAE), this should not be considered a “verified therapy.”
Priority Ranking (Evidence Strength + PDAC Relevance)
| Rank | Project | Evidence | Risk | Key Signal |
|---|---|---|---|---|
| 1 | Neo-P DC (Japan) | B | Low | 7 adjuvant patients, 61mo follow-up, 1 recurrence, 0 deaths |
| 2 | WT1 DC | B | Medium | Prospective Phase I with OS/PFS, 50% conversion surgery rate |
| 3 | P01 (iNeo-Vac-P01) | B | Low-Medium | 3yr RFS 83.3% in 9 post-surgery patients (abstract) |
| 4 | PCNAT-01 | C | Medium | 3-5yr RFS signal from preliminary abstract |
| 5 | RGL-270 | C | Medium-High | I期 recruiting, ICI combination cohort raises irAE risk |
| 6 | XH001 | C | Medium | I期 recruiting, no readout |
| 7 | LK101 | C | Medium | No PDAC-specific data |
Key Insight: Vaccines Work Better After Surgery
A critical takeaway from the literature: PDAC vaccines are more likely to work in the adjuvant/MRD (minimal residual disease) setting, not in advanced disease. Why?
- Lower tumor burden
- Weaker immunosuppressive microenvironment
- Better ratio of effector T cells to target tumor cells
This means the “right” strategy is: complete standard post-surgery treatment → enter vaccine trial with no radiological recurrence → measure RFS/OS as the real endpoint — not just ELISpot or T-cell counts.
Marketing vs. Data: Red Flags to Watch
- “FDA Orphan Drug Designation” ≠ “proven clinical benefit.” ODD is a regulatory milestone, not an efficacy signal.
- “X-year RFS of Y%” from only 5–10 patients is a signal, not a conclusion. Small samples can produce dramatic percentages by chance.
- No public ≥Grade 3 AE data is a hard stop. If a project hasn’t disclosed CTCAE-graded adverse event tables, the safety profile is unverified regardless of how promising the mechanism looks.
- “Immune response detected” (ELISpot, TCR expansion) is a necessary but insufficient condition. Immune response ≠ clinical benefit until proven in adequately powered studies.
What International Patients Should Do
- Get molecular profiling first. KRAS mutation type (G12D/G12V/G12C), HLA typing, and tumor mutational burden determine which trials you’re eligible for.
- Complete standard treatment before considering vaccines. Surgery → adjuvant chemo → no evidence of disease → then evaluate vaccine trials.
- Ask the hard questions. What is the complete AE profile? Has ≥Grade 3 toxicity been reported? What is the actual RFS/OS data (not just immune response)?
- Use the clinical trials page. See our Clinical Trials page for a complete list of active PDAC vaccine and targeted therapy trials in China.
This report was compiled from peer-reviewed publications, ClinicalTrials.gov registrations, conference abstracts, and publicly available hospital data. Last updated: April 2026. This article does not constitute medical advice.
Special acknowledgment: The evidence grading framework and data compilation in this report were developed with deep research methodology to ensure verifiability.